Home/VahatiCor/Kevin Van Bladel

KV

Kevin Van Bladel

Chief Technology Officer

Therapeutic Areas

VahatiCor Pipeline

Drug	Indication	Phase
A-FLUX Reducer System	Coronary Microvascular Dysfunction (CMD)	Early Feasibility

Leadership Team at VahatiCor

Founder and Chairman

Head of Corporate Development

VP of Regulatory and Quality Affairs

Janie Mandrusov

VP, Clinical Affairs

View full VahatiCor profile